Kaken Pharmaceutical Company Description
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.
The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions.
It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens.
In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia.
Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective next-generation oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan.
Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1917 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,135 |
| CEO | Hiroyuki Horiuchi |
Contact Details
Address: 28-8, Honkomagome 2-chome Tokyo, 113-8650 Japan | |
| Phone | 81 3 5977 5007 |
| Website | kaken.co.jp |
Stock Details
| Ticker Symbol | KKPCF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3207000005 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hiroyuki Horiuchi | Chairman, President and Representative Director |
| Tomoyuki Koseki | Chief Officer of Marketing and Sales Division |
| Satoshi Murakami | Chief Officer of Regulatory Affairs Division |
| Hironobu Ogura | Chief of Drug Research Centers |
| Masashi Suzudo | MD and Director |
| Hirofumi Fujii | Corporate Officer |
| Mitsuru Watanuki | Head of Research and Development and Director |
| Masaru Ogawa | Director of Pharmaceutical Affairs Division |
| Tatsuhiro Harada | Deputy Chief Officer of Research & Development Division and Chief of Drug Research Center |
| Keizo Kimura | Chief Officer of Production Division and Chief of Shizuoka Factory |